Jump to main content
Jump to site search

Issue 1, 2006
Previous Article Next Article

The mechanism of action of ramoplanin and enduracidin

Author affiliations


The lipoglycodepsipeptide antibiotic ramoplanin is proposed to inhibit bacterial cell wall biosynthesis by binding to intermediates along the pathway to mature peptidoglycan, which interferes with further enzymatic processing. Two sequential enzymatic steps can be blocked by ramoplanin, but there is no definitive information about whether one step is inhibited preferentially. Here we use inhibition kinetics and binding assays to assess whether ramoplanin and the related compound enduracidin have an intrinsic preference for one step over the other. Both ramoplanin and enduracidin preferentially inhibit the transglycosylation step of peptidoglycan biosynthesis compared with the MurG step. The basis for stronger inhibition is a greater affinity for the transglycosylase substrate Lipid II over the MurG substrate Lipid I. These results provide compelling evidence that ramoplanin's and enduracidin's primary cellular target is the transglycosylation step of peptidoglycan biosynthesis.

Graphical abstract: The mechanism of action of ramoplanin and enduracidin

Back to tab navigation

Publication details

The article was received on 28 Oct 2005, accepted on 16 Nov 2005 and first published on 29 Nov 2005

Article type: Paper
DOI: 10.1039/B515328J
Citation: Mol. BioSyst., 2006,2, 69-76
  •   Request permissions

    The mechanism of action of ramoplanin and enduracidin

    X. Fang, K. Tiyanont, Y. Zhang, J. Wanner, D. Boger and S. Walker, Mol. BioSyst., 2006, 2, 69
    DOI: 10.1039/B515328J

Search articles by author